Send me a link:

*Text messaging rates may apply.

 Dow Down0.28% Nasdaq Down0.17%

Alimera Sciences, Inc. (ALIM)

-NasdaqGM
5.76 0.14(2.37%) Jul 21, 3:59PM EDT
ProfileGet Profile for:
Alimera Sciences, Inc.
6120 Windward Parkway
Suite 290
Alpharetta, GA 30005
United States - Map
Phone: 678-990-5740
Fax: 678-990-5744
Website: http://www.alimerasciences.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Major
Full Time Employees:31

Business Summary 

Alimera Sciences, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company’s principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient’s eye to a placement site that uses the eye’s natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Alimera Sciences, Inc.

Corporate Governance 
Alimera Sciences, Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 10. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 10; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Charles Daniel Myers , 60
Co-Founder, Chief Exec. Officer, Pres and Director
556.00K0.00
Mr. Richard S. Eiswirth Jr., 46
Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer, VP, Treasurer and Sec.
382.00K0.00
Dr. Kenneth Green Ph.D., 56
Chief Scientific Officer and Sr. VP
361.00K0.00
Mr. David R. Holland , 50
Co-Founder and Sr. VP of Sales & Marketing
N/AN/A
Ms. Susan H. Caballa , 70
Sr. VP of Regulatory and Technical Affairs
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders